AIM ImmunoTech Inc. (NYSE:AIM - Get Free Report) CEO Thomas K. Equels purchased 60,110 shares of the company's stock in a transaction that occurred on Wednesday, November 20th. The shares were purchased at an average cost of $0.18 per share, with a total value of $10,819.80. Following the completion of the acquisition, the chief executive officer now owns 1,552,968 shares in the company, valued at $279,534.24. The trade was a 4.03 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
AIM ImmunoTech Stock Performance
AIM ImmunoTech stock opened at $0.20 on Thursday. AIM ImmunoTech Inc. has a 52-week low of $0.16 and a 52-week high of $0.62. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a 50 day moving average price of $0.26 and a two-hundred day moving average price of $0.33.
Analyst Upgrades and Downgrades
AIM has been the subject of a number of recent analyst reports. Ascendiant Capital Markets cut their target price on AIM ImmunoTech from $5.25 to $5.00 and set a "buy" rating for the company in a research report on Tuesday, September 3rd. Maxim Group cut their price objective on shares of AIM ImmunoTech from $2.00 to $1.00 and set a "buy" rating for the company in a research report on Tuesday, October 22nd.
Breaking News: Tesla headed to $500…
From WealthPress | Ad
That headline hit late last night…and the rally has begun
Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
So to claim your free digital copy today, simply follow this link and enter your email address.
Get Our Latest Stock Analysis on AIM ImmunoTech
Institutional Investors Weigh In On AIM ImmunoTech
An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC bought a new stake in AIM ImmunoTech Inc. (NYSE:AIM - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 4,078,000 shares of the company's stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is currently owned by institutional investors and hedge funds.
About AIM ImmunoTech
(
Get Free Report)
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
